BioLife Solutions Q1 revenue up 25% YoY to $27.5M; net income $1.2M

BIOLIFE SOLUTIONS INC

2026-Q1 EPS reported $0.02 revenue$27,500,000

Total revenue $27.5M, +25% YoY from $22.1M; GAAP net income $1.2M vs $0.3M in Q1 2025.
Non-GAAP adjusted EBITDA $6.2M (22% of revenue) vs $5.4M (24% of revenue) in Q1 2025.
GAAP EPS $0.02; GAAP gross margin 64% (down from 67% YoY); adjusted gross margin 64% (down from 68%).
Reiterated FY 2026 guidance: revenue $112.5-115.0M, mid-60% gross margin, full-year net income.
Biopreservation media embedded in 17 commercial CGTs and ~250 ongoing U.S. clinical trials (70% share).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOLIFE SOLUTIONS INC reported the three months ended March 31, 2026 results: revenue $27.5 million, net income $1.2 million, EPS $0.02. Guidance reaffirmed.

Period: the three months ended March 31, 2026
Revenue: $27.5 million
Net income: $1.2 million
EPS: $0.02
Guidance: reaffirmed
Result: reported results

Exact text from the filing

BioLife Solutions Reports First Quarter 2026 Financial Results Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue

View on SEC.gov

Browse all earnings releases →

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001628280-26-032123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.